CORCEPT THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures and Power of Attorney
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CORCEPT THERAPEUTICS INCORPORATED | |
| By: | /s/ JOSEPH K. BELANOFF |
| Joseph K. Belanoff, M.D., | |
| Chief Executive Officer and President | |
| Date: | February 15, 2024 |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Joseph K. Belanoff and Atabak Mokari, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Exchange Act, this Annual Report on Form 10-K has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ JOSEPH K. BELANOFF | Chief Executive Officer, President and Director | February 15, 2024 |
| Joseph K. Belanoff, M.D. | (Principal Executive Officer) | |
| /s/ ATABAK MOKARI | Chief Financial Officer | February 15, 2024 |
| Atabak Mokari | (Principal Financial Officer) | |
| /s/ JOSEPH DOUGLAS LYON | Chief Accounting Officer | February 15, 2024 |
| Joseph Douglas Lyon | (Principal Accounting Officer) | |
| /s/ JAMES N. WILSON | Director and Chairman of the Board of Directors | February 15, 2024 |
| James N. Wilson | ||
| /s/ GREGG ALTON | Director | February 15, 2024 |
| Gregg Alton | ||
| /s/ G. LEONARD BAKER, JR. | Director | February 15, 2024 |
| G. Leonard Baker, Jr. | ||
| /s/ GILLIAN CANNON | Director | February 15, 2024 |
| Gillian Cannon | ||
| /s/ DAVID L. MAHONEY | Director | February 15, 2024 |
| David L. Mahoney | ||
| /s/ JOSHUA MURRAY | Director | February 15, 2024 |
| Joshua Murray | ||
| /s/ KIMBERLY PARK | Director | February 15, 2024 |
| Kimberly Park | ||
| /s/ DANIEL N. SWISHER, JR | Director | February 15, 2024 |
| Daniel N. Swisher, Jr. | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (EY US PCAOB #42) | F-2 |
|---|---|
| Audited Financial Statements | |
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Income | F-5 |
| Consolidated Statements of Comprehensive Income | F-6 |
| Consolidated Statements of Cash Flows | F-7 |
| Consolidated Statement of Stockholders’ Equity | F-9 |
| Consolidated Notes to Financial Statements | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.